BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Expands Corporate Efforts as It Advances Closer to Market with Milestone Products

February 17, 2022 11:21:04

AREV Life Sciences (CSE: AREV) (OTC: AREVF) today announced new corporate acquisitions and maturation of multiple product lines being matched with appointments and expanding corporate capacity in the company’s scientific advisory committee and IP council. The company has appointed Douglas Sorocco to its scientific advisory committee and IP council and has extended services with Strategic Health Resources LLC. These moves come as AREV’s expanding consumer products and therapeutic innovations pipeline enters mature stages of development. “These new additions to AREV’s corporate efforts assure acceleration of the enterprise’s immediate goals as we come closer to market entry with milestone products,” said Mike Withrow, CEO of AREV Life Sciences. “Our corporate leadership is fully committed to keeping pace with the capacities of both senior management and our advisory boards as we advance product development and research efforts in our human nutrition and preclinical phytomedicinal therapeutic research with a range of emerging corporate partners, in order to deliver value to the investors and create paradigm shifts in the treatment of inanition and to address other clinical disparities facing patient populations and the general consumer marketplace.”

To view the full press release, visit

About AREV Life Sciences Global Corp.

AREV Life Sciences is a fully integrated, publicly traded, early stage life science enterprise dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations in human nutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (“BIO”). For more information, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork